.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,789,395

« Back to Dashboard

Claims for Patent: 5,789,395

Title: Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
Abstract:A method is disclosed for inhibiting endogenous production of nitric oxide (NO) in an in vivo, in vitro, or ex vivo mammalian system. The method employs a tetracycline compound to inhibit production of NO and/or to inhibit the expression or activity of an inducible isoform of nitric oxide synthase (iNOS). Preferably, the tetracycline compound has inhibitory activity for metalloproteinases. Also it is preferred that the tetracycline compound is provided to the mammalian system in an amount which has little or no antibacterial activity in the system. Accordingly, preferred tetracycline compounds are tetracycline compounds which have be modified to reduce or eliminate their antimicrobial activity. The method can be used to treat medical conditions in mammals characterized by NO production mediated by iNOS, including, for example, inflammatory conditions.
Inventor(s): Amin; Ashok R. (Union, NJ), Abramson; Steven B. (Rye, NY), Golub; Lorne M. (Smithtown, NY), Ramamurthy; Nungavaram S. (Smithtown, NY), McNamara; Thomas F. (Port Jefferson, NY), Greenwald; Robert A. (Melville, NY), Trachtman; Howard (New Rochelle, NY)
Assignee: The Research Foundation of State University of New York (Albany, NY) Hospital for Joint Diseases (New York, NY)
Application Number:08/697,815
Patent Claims: 1. A method for inhibiting nitric oxide production in a mammal system, comprising providing to the mammalian system an amount of a tetracycline compound sufficient to cause a decrease in the amount of nitric oxide produced endogenously by the mammalian-system.

2. The method according to claim 1, wherein the tetracycline compound has substantially no anti-microbial activity in the mammal system.

3. The method according to claim 1, wherein the tetracycline compound has metalloproteinase inhibitory activity.

4. The method according to claim 1, wherein the tetracycline compound is 6-demethyl-6-deoxy-4-dedimethylaminotetracycline (CMT-3), 6-.alpha.-deoxy-5-hydroxy-4-dedimethylaminotetracycline (CMT-8), 4-dedimethylaminotetracycline (CMT- 1), doxycycline, or minocycline.

5. The method according to claim 1, wherein said mammal has a condition characterized by increased endogenous nitric oxide production.

6. The method according to claim 5, wherein said mammal has nitric oxide-dependent glomerular inflammation.

7. The method according to claim 5, wherein said mammal has osteoarthritis.

8. The method according to claim 1, wherein said method further comprises providing to said mammal an anti-inflammatory amount of a steroidal or non-steroidal anti-inflammatory drug.

9. The method according to claim 1, wherein said mammal has a condition characterized by an abnormally high level of activity of inducible nitric oxide synthase.

10. A method for inhibiting nitric oxide production in an in vitro mammalian cell culture or an ex vivo mammalian tissue culture or mammalian organ comprising providing to said cell culture, tissue culture or organ an amount of a tetracycline compound sufficient to inhibit endogenous nitric oxide production in said cell culture, tissue culture, or organ wherein a measured amount of nitric oxide production is indicative of expression or activity of inducible nitric oxide synthase.

11. A method for treating a mammal having a medical condition characterized by excess endogenous production of nitric oxide, comprising administering to the mammal an amount of a tetracycline compound sufficient to inhibit endogenous nitric oxide production in the mammal.

12. The method according to claim 11, wherein the medical condition is an acute inflammatory condition.

13. The method according to claim 11, wherein the medical condition is a chronic inflammatory condition.

14. The method according to claim 11, wherein the tetracycline compound has substantially no anti-microbial activity in the mammal.

15. The method according to claim 11, wherein the tetracycline compound has metalloproteinase inhibitory activity.

16. The method according to claim 11, wherein the tetracycline compound is 6-demethyl-6-deoxy-4-dedimethylaminotetracycline (CMT-3), 6-.alpha.-deoxy-5-hydroxy-4-dedimethylaminotetracycline (CMT-8), 4-dedimethylaminotetracycline (CMT- 1), doxycycline, or minocycline.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc